Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients

Author:

Rivero-Juarez Antonio,Vallejo Nicolau,Lopez-Lopez PedroORCID,Díaz-Mareque Ana Isabel,Frias Mario,Vallejo Aldara,Caballero-Gómez Javier,Rodríguez-Velasco María,Molina Esther,Aguilera Antonio

Abstract

The hepatitis E virus (HEV) is the major cause of acute hepatitis of viral origin worldwide. Despite its usual course as an asymptomatic self-limited hepatitis, there are highly susceptible populations, such as those with underlying immunosuppression, which could develop chronic hepatitis. In this situation, implementation of therapy is mandatory in the sense to facilitate viral clearance. Currently, there are no specific drugs approved for HEV infection, but ribavirin (RBV), the drug of choice, is used for off-label treatment. Here, we present two cases of chronic HEV infection in transplant patients, reviewing and discussing the therapeutic approach available in the literature. The use of RBV for the treatment of an HEV infection in organ transplant patients seems to be effective. The recommendation of 12 weeks of therapy is adequate in terms of efficacy. Nevertheless, there are important issues that urgently need to be assessed, such as optimal duration of therapy and drug dosage.

Funder

Instituto de Salud Carlos III

Publisher

MDPI AG

Subject

Virology,Microbiology (medical),Microbiology

Reference69 articles.

1. Origin and dispersal of Hepatitis E virus

2. Avian Hepatitis E Virus: With the Trend of Genotypes and Host Expansion

3. Global Hepatitis Report 2017http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

4. Waterborne Outbreaks of Hepatitis E: Recognition, Investigation and Controlhttps://www.who.int/hepatitis/publications/HepE-manual/en/

5. Case-control study on risk factors for acute hepatitis E in Germany, 2012 to 2014

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3